Welcome to our dedicated page for Janux Therapeutics news (Ticker: JANX), a resource for investors and traders seeking the latest updates and insights on Janux Therapeutics stock.
Janux Therapeutics, Inc. (Nasdaq: JANX) is a clinical-stage biopharmaceutical company whose news flow is closely tied to the progress of its tumor-activated immunotherapy platforms. The company regularly issues updates on its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) programs, making JANX news particularly relevant for followers of immuno-oncology and autoimmune disease research.
Investors and analysts tracking JANX can expect news items covering clinical trial updates for its lead TRACTr candidates, JANX007 and JANX008. Press releases describe Phase 1 data in metastatic castration-resistant prostate cancer for JANX007, including safety, radiographic progression-free survival and dosing strategies, as well as Phase 1 development of JANX008 in multiple advanced or metastatic solid tumors such as colorectal carcinoma, head and neck squamous cell carcinoma, several lung cancer subtypes, renal cell carcinoma, pancreatic ductal adenocarcinoma and triple-negative breast cancer.
Janux also issues R&D and pipeline communications, including R&D Day events that highlight preclinical advances in PSMA-TRACIr, TROP2-TRACTr and the CD19-ARM program. These announcements often discuss preclinical data, planned IND-enabling activities and anticipated timelines for moving candidates toward first-in-human trials. In addition, JANX news includes financial results and business highlights, where the company reports quarterly performance, research and development spending, and enrollment status for ongoing trials.
Another recurring category of news involves collaboration milestones, such as the clinical milestone payment triggered under Janux’s TRACTr collaboration with Merck. Corporate updates, including leadership appointments and strategic development commentary, also appear in the company’s releases. For a consolidated view of these developments, the JANX news page on Stock Titan aggregates earnings releases, clinical data announcements, R&D events and collaboration updates in one place for ongoing monitoring.
Janux Therapeutics (Nasdaq: JANX) reported Q4 and full-year 2025 results highlighting clinical progress, a strategic collaboration with Bristol Myers Squibb, leadership hiring, and a strong year-end balance sheet. Key metrics include $966.6M cash and investments, Phase 1 activity across JANX007/008/011, and a $50M near-term collaboration payment.
Clinical readouts show median rPFS of 7.9–8.9 months for JANX007 and confirmed/unconfirmed partial responses in 30% (8/27) of RECIST-evaluable patients. Company expects additional 2026 updates.
Janux Therapeutics (Nasdaq: JANX) announced dosing of the first participant in a Phase 1 study of JANX011, a CD19-targeted bispecific from its ARM platform designed for autoimmune diseases.
JANX011 produced deep, durable B-cell depletion and memory B-cell reset in preclinical single-dose studies across a >100-fold dose range with low cytokine levels; the open-label, dose-escalation trial (NCT07291323) will assess safety, PK, and PD in healthy adults to inform dose selection and indication prioritization.
Janux Therapeutics (NASDAQ:JANX) appointed William Go, M.D., Ph.D., as Chief Medical Officer effective January 26, 2026. Dr. Go succeeds Zachariah McIver, D.O., Ph.D., and brings more than 20 years of hematology and oncology experience, including leadership on the pivotal ZUMA-1 trial and development roles at A2 Biotherapeutics, Kite Pharma, and Amgen.
Janux is advancing multiple early-stage programs: JANX007 (PSMA TRACTr) and JANX008 (EGFR TRACTr) in Phase 1 trials across prostate and several solid tumor indications, plus additional TRACTr/TRACIr and an ARM CD19 program aimed at autoimmune diseases.
Janux Therapeutics (NASDAQ: JANX) on January 22, 2026 announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb to develop a novel tumor-activated therapeutic targeting a validated solid tumor antigen.
Under the deal Janux will complete preclinical work through IND submission; Bristol Myers Squibb will hold the IND and lead subsequent development and global commercialization while Janux supports completion of the first Phase 1 study.
Financial terms include up to $50 million in upfront and near-term milestone payments, up to approximately $800 million in development, regulatory and commercial milestones, plus tiered royalties on global sales.
Janux Therapeutics (Nasdaq: JANX) provided a program update on its Phase 1 study of JANX008, an EGFR-targeted TRACTr for multiple solid tumors.
The company said the Phase 1a dose-escalation portion (NCT05783622) is complete and expansion cohorts have been initiated to further evaluate safety, PK/PD and evidence of clinical activity across selected tumor types; Janux expects additional updates as data mature.
Janux also summarized its pipeline: JANX007 (PSMA-TRACTr) in Phase 1 for mCRPC, additional CD3-TRACTr and CD28-TRACIr programs (including PSMA-TRACIr and TROP2-TRACTr), and a CD19-ARM program advancing toward clinical evaluation.
Janux (NASDAQ: JANX) reported updated interim Phase 1 data for JANX007, a PSMA-directed TRACTr in mCRPC, with data cut-off Oct 15, 2025. Across Phase 1a/b, 109 patients were treated; Phase 1a patients had a median of 4 prior lines of therapy while Phase 1b enrolled taxane-naïve patients.
Key efficacy signals include confirmed/unconfirmed partial responses in 30% (8/27) of RECIST-evaluable patients and rPFS of 7.9–8.9 months. Taxane-naïve expansion showed rapid, deep PSA reductions. Safety was described as manageable with CRS primarily grade 1–2 limited to cycle 1 and an identified CRS mitigation strategy. Janux plans monotherapy and darolutamide combinations and will evaluate PARP inhibitor–refractory patients.
Janux Therapeutics (NASDAQ: JANX) will host a virtual event on December 1, 2025 at 4:30 PM ET where CEO David Campbell, Ph.D. will present updated clinical data for JANX007.
The presentation will emphasize Phase 1a dose-escalation results and secondarily cover Phase 1b expansion data in adult subjects with metastatic castration-resistant prostate cancer (mCRPC), followed by a live analyst Q&A. Registration is required to attend.
The release also summarizes Janux's development pipeline including JANX008 (EGFR TRACTr), additional CD3 TRACTr and CD28 TRACIr programs, a PSMA-TRACIr intended for combination use with JANX007, a TROP2-TRACTr, and a CD19-ARM program targeting autoimmune disease.
Janux Therapeutics (NASDAQ: JANX) reported third-quarter 2025 results and a business update on November 6, 2025. Key points: cash and short-term investments of $989.0 million as of September 30, 2025; ongoing enrollment in first-in-human Phase 1 trials for JANX007 (mCRPC) and JANX008 (advanced/metastatic solid tumors); additional JANX007 and JANX008 data expected in the fourth quarter of 2025.
Quarterly results: R&D expense $34.6M (Q3 2025) vs $18.6M (Q3 2024); G&A expense $10.6M vs $17.7M; net loss $24.3M vs $28.1M. Pipeline updates include multiple TRACTr, TRACIr and ARM candidates and planned clinic entries next year.
Janux Therapeutics (NASDAQ:JANX) reported Q2 2025 financial results and business updates, highlighting progress across its TRACTr, TRACIr, and ARM platforms. The company maintains a strong financial position with $996.0 million in cash and investments, down slightly from $1.03 billion at year-end 2024.
Key developments include ongoing enrollment in Phase 1 trials for JANX007 (targeting PSMA in mCRPC) and JANX008 (targeting EGFR in multiple solid tumors). Janux received a $10 million milestone payment from Merck following the first patient dosing in their lead collaboration program. The company's July R&D Day showcased new candidates including a PSMA-TRACIr, TROP2-TRACTr, and CD19-ARM for autoimmune diseases.
Q2 financial results showed increased R&D expenses of $34.7 million and a net loss of $33.9 million, reflecting expanded clinical development activities.
Janux Therapeutics (Nasdaq: JANX) has achieved a significant clinical milestone in its TRACTr collaboration with Merck, triggering a $10 million milestone payment. The achievement marks the dosing of the first patient in their collaborative program, stemming from their December 2020 partnership.
The company is advancing multiple clinical programs, including JANX007, a PSMA-targeting TRACTr in Phase 1 trials for mCRPC, and JANX008, an EGFR-targeting TRACTr being studied across multiple solid cancers. Janux is also developing additional CD3-based TRACTr and CD28-based TRACIr programs, including a PSMA-TRACIr and TROP2-TRACTr, alongside their first ARM platform program targeting CD19 for autoimmune diseases.